Cargando…

Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report

The combined immunotherapy of nivolumab and ipilimumab causes a variety of autoimmune-related adverse events (irAEs). The current report details a 70-year-old woman with clear cell renal cell carcinoma metastasis in the lung. Two weeks after two courses of treatment, the patient complained of headac...

Descripción completa

Detalles Bibliográficos
Autores principales: Takamatsu, Dai, Furubayashi, Nobuki, Negishi, Takahito, Ieiri, Kosuke, Inoue, Tomohiro, Tsukino, Keiji, Nakamura, Motonobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826270/
https://www.ncbi.nlm.nih.gov/pubmed/31700625
http://dx.doi.org/10.3892/mco.2019.1929
_version_ 1783465046393749504
author Takamatsu, Dai
Furubayashi, Nobuki
Negishi, Takahito
Ieiri, Kosuke
Inoue, Tomohiro
Tsukino, Keiji
Nakamura, Motonobu
author_facet Takamatsu, Dai
Furubayashi, Nobuki
Negishi, Takahito
Ieiri, Kosuke
Inoue, Tomohiro
Tsukino, Keiji
Nakamura, Motonobu
author_sort Takamatsu, Dai
collection PubMed
description The combined immunotherapy of nivolumab and ipilimumab causes a variety of autoimmune-related adverse events (irAEs). The current report details a 70-year-old woman with clear cell renal cell carcinoma metastasis in the lung. Two weeks after two courses of treatment, the patient complained of headache, dizziness and nausea. Cerebrospinal fluid (CSF) analysis revealed an elevated protein level of 195 mg/dl and a significantly elevated white blood cell (WBC) count of 830/mm(3) (lymphocytes, 825/mm(3); neutrophils, 5/mm(3)). The results excluded malignancy and infection. The patient was diagnosed with aseptic meningitis and was administered intravenous prednisolone (1 mg/kg/day). On the 49th day of the 2nd course of treatment, no recurrence of clinical symptoms was exhibited during maintenance oral steroid treatment (prednisolone 10 mg/day) and CSF analysis revealed that the WBC count had dropped to 44/mm(3) (lymphocytes only). Therefore, the 3rd course of treatment was readministered the next day. After two weeks, the patients again complained of nausea, anorexia and fatigue. CSF analysis demonstrated that the WBC count was not increased from the result obtained previously. However, brain MRI scans revealed the mild diffuse enlargement of the pituitary and endocrine system tests revealed reduced adrenocorticotropic hormone (ACTH; 2.0 pg/ml) and cortisol (1.12 µg/dl) levels. The patient was diagnosed with isolated ACTH deficiency and oral hydrocortisone was administered after prednisolone cessation. On the 25th day of the 3rd course of treatment, the patient complained of headache and anorexia. CSF examination revealed that the WBC count had increased a second time (53/mm(3); lymphocytes only) and laboratory data revealed hepatic dysfunction. The patient was then diagnosed with relapse of aseptic meningitis and liver dysfunction. While continuing oral hydrocortisone treatment, the administration of intravenous prednisolone was started. The observed liver dysfunction and aseptic meningitis gradually improved. The current report may be useful for avoiding delays in the diagnosis and treatment of this life-threatening and uncommon irAE, in which CSF examinations are useful for diagnosis and management.
format Online
Article
Text
id pubmed-6826270
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-68262702019-11-07 Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report Takamatsu, Dai Furubayashi, Nobuki Negishi, Takahito Ieiri, Kosuke Inoue, Tomohiro Tsukino, Keiji Nakamura, Motonobu Mol Clin Oncol Articles The combined immunotherapy of nivolumab and ipilimumab causes a variety of autoimmune-related adverse events (irAEs). The current report details a 70-year-old woman with clear cell renal cell carcinoma metastasis in the lung. Two weeks after two courses of treatment, the patient complained of headache, dizziness and nausea. Cerebrospinal fluid (CSF) analysis revealed an elevated protein level of 195 mg/dl and a significantly elevated white blood cell (WBC) count of 830/mm(3) (lymphocytes, 825/mm(3); neutrophils, 5/mm(3)). The results excluded malignancy and infection. The patient was diagnosed with aseptic meningitis and was administered intravenous prednisolone (1 mg/kg/day). On the 49th day of the 2nd course of treatment, no recurrence of clinical symptoms was exhibited during maintenance oral steroid treatment (prednisolone 10 mg/day) and CSF analysis revealed that the WBC count had dropped to 44/mm(3) (lymphocytes only). Therefore, the 3rd course of treatment was readministered the next day. After two weeks, the patients again complained of nausea, anorexia and fatigue. CSF analysis demonstrated that the WBC count was not increased from the result obtained previously. However, brain MRI scans revealed the mild diffuse enlargement of the pituitary and endocrine system tests revealed reduced adrenocorticotropic hormone (ACTH; 2.0 pg/ml) and cortisol (1.12 µg/dl) levels. The patient was diagnosed with isolated ACTH deficiency and oral hydrocortisone was administered after prednisolone cessation. On the 25th day of the 3rd course of treatment, the patient complained of headache and anorexia. CSF examination revealed that the WBC count had increased a second time (53/mm(3); lymphocytes only) and laboratory data revealed hepatic dysfunction. The patient was then diagnosed with relapse of aseptic meningitis and liver dysfunction. While continuing oral hydrocortisone treatment, the administration of intravenous prednisolone was started. The observed liver dysfunction and aseptic meningitis gradually improved. The current report may be useful for avoiding delays in the diagnosis and treatment of this life-threatening and uncommon irAE, in which CSF examinations are useful for diagnosis and management. D.A. Spandidos 2019-12 2019-10-03 /pmc/articles/PMC6826270/ /pubmed/31700625 http://dx.doi.org/10.3892/mco.2019.1929 Text en Copyright: © Takamatsu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Takamatsu, Dai
Furubayashi, Nobuki
Negishi, Takahito
Ieiri, Kosuke
Inoue, Tomohiro
Tsukino, Keiji
Nakamura, Motonobu
Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report
title Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report
title_full Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report
title_fullStr Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report
title_full_unstemmed Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report
title_short Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report
title_sort relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: a case report
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826270/
https://www.ncbi.nlm.nih.gov/pubmed/31700625
http://dx.doi.org/10.3892/mco.2019.1929
work_keys_str_mv AT takamatsudai relapseofasepticmeningitisinducedbyipilimumabandnivolumabtherapyformetastaticrenalcellcarcinomaacasereport
AT furubayashinobuki relapseofasepticmeningitisinducedbyipilimumabandnivolumabtherapyformetastaticrenalcellcarcinomaacasereport
AT negishitakahito relapseofasepticmeningitisinducedbyipilimumabandnivolumabtherapyformetastaticrenalcellcarcinomaacasereport
AT ieirikosuke relapseofasepticmeningitisinducedbyipilimumabandnivolumabtherapyformetastaticrenalcellcarcinomaacasereport
AT inouetomohiro relapseofasepticmeningitisinducedbyipilimumabandnivolumabtherapyformetastaticrenalcellcarcinomaacasereport
AT tsukinokeiji relapseofasepticmeningitisinducedbyipilimumabandnivolumabtherapyformetastaticrenalcellcarcinomaacasereport
AT nakamuramotonobu relapseofasepticmeningitisinducedbyipilimumabandnivolumabtherapyformetastaticrenalcellcarcinomaacasereport